Suicide gene/prodrug therapy using salmonella-mediated delivery of Escherichia coli purine nucleoside phosphorylase gene and 6-methoxypurine 2′-deoxyriboside in murine mammary carcinoma 4T1 model

Cancer Science

Volumn 99, Issue 6, 2008, Pages 1172-1179

  Fu, Wei ^a   Lan, Hekui ^a   Liang, Shenghua ^a   Gao, Tong ^a   Ren, Daming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXYPURINE 2' DEOXYRIBOSIDE; CASPASE 3; GREEN FLUORESCENT PROTEIN; PROPIDIUM IODIDE; PURINE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GENE; BREAST CARCINOMA; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMETRY; CYTOTOXICITY; DRUG ACCUMULATION; ESCHERICHIA COLI; FEMALE; GENE CONTROL; GENE CONVERSION; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE FUNCTION; GENE VECTOR; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; SALMONELLA TYPHIMURIUM; SUICIDE GENE THERAPY; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BYSTANDER EFFECT; CASPASE 3; CELL PROLIFERATION; COMBINED MODALITY THERAPY; ESCHERICHIA COLI; FEMALE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; PRODRUGS; PROMOTER REGIONS (GENETICS); PURINE NUCLEOSIDES; PURINE-NUCLEOSIDE PHOSPHORYLASE; SALMONELLA; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 43549110773     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00808.x     Document Type: Article

References (60)

1. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005; 102: 14034-9.
2. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57: 4537-44.
3. Low KB, Ittensohn M, Le T et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol 1999; 17: 37-41.
4. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003; 4: 548-56.
5. Clairmont C, Lee KC, Pike J et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 2000; 181: 1996-2002.
6. Steven A, Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002; 25: 218-25.
7. Saltzman DA, Katsanis E, Heise CP et al. Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: A novel antitumor agent? J Ped Surg 1997; 32: 301-6.
8. Toso JF, Gill VJ, Hwu P et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20: 142-52.
9. Zhao M, Yang M, Li X-M et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755-60.
10. Zhao M, Yang M, Ma H et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006; 66: 7647-52.
11. Zhao M, Jack G, Ma HY, Yang M, Sheldon P, Robert MH. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 2007; 104: 10170-4.
12. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349-59.
13. Barzon L, Boscaro M, Palù G. Endocrine aspects of cancer gene therapy. Endocr Rev 2004; 25: 1-44.
14. Lee CH, Wu CL, Shiau AL. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 2005; 6: 1382-93.
15. Lee CH, Wu CL, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 2005; 12: 175-84.
16. Li X, Fu GF, Fan YR et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105-11.
17. King I, Bermudes D, Lin S et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum Gene Ther 2002; 13: 1225-33.
18. Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophagemediated cytotoxicity against murine bladder cancer MBT-2. J Urol 2000; 164: 526-31.
19. Agorio C, Schreiber F, Sheppard M et al. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 2007; 9: 416-23.
20. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene and generation of toxic purines. Gene Ther 1994; 1: 233-8.
21. Jensen KF, Nygaard P. Purine nucleoside phosphorylase from Escherichia coli and Salmonella typhimurium. Purification and some properties. Eur J Biochem 1975; 51: 253-65.
22. Ealick SE, Greenhough TJ, Babu YS et al. Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 Å resolution. J Biol Chem 1990; 265: 1812-20.
23. Mao C, Cook WJ, Zhou M, Koszalka GW, Krenitsky TA, Ealick SE. The crystal structure of Escherichia coli purine nucleoside phosphorylase: A comparison with the human enzyme reveals a conserved topology. Structure 1997; 5: 1373-83.
24. Secrist JA III, Parker WB, Allan PW et al. Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 1999; 18: 745-57.
25. Bzowska A, Kulikowska E, Shugar D. Purine nucleoside phosphorylases: properties, functions and clinical aspects. Pharmacol Therapeutics 2000; 88: 349-425.
26. Hughes B, Parker WB, Gadi VK, Garver RI, Sorscher EJ. Tumor specific killing with high bystander toxicity using the human tyrosinase promoter to express the E.coli PNP gene. Cancer Res 1995; 55: 3339-45.
27. Lockett LJ, Molloy PL, Russell PJ, Both GW. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res 1997; 3: 2075-80.
28. Park BJ, Brown CK, Hu Y et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther 1999; 10: 889-98.
29. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of tumor cells. Gene Ther 2000; 7: 1738-43.
30. Krohne TU, Shankara S, Geissler M et al. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 2001; 34: 511-18.
31. Da Costa L, Jen J, He TC, Kinzler KW, Vogelstein B. Converting cancer genes into killer genes. Proc Natl Acad Sci USA 1996; 93: 4192-6.
32. Nestler UM, Heinkelein M, Lucke J et al. Foamy virus vectors for suicide gene therapy. Gene Ther 1997; 4: 1270-7.
33. Parker WB, King SA, Allan PW et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 1997; 8: 1637-44.
34. Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ. Cell to cell contact is not required for bystander cell killing by E.coli purine nucleoside phosphorylase. J Biol Chem 1998; 273: 2322-8.
35. Bharara S, Sorscher EJ, Gillespie GY et al. Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for Herpes simplex virus based glioma therapy. Hum Gene Ther 2005; 16: 1-9.
36. Martiniello-Wilks R, Dane A, Jeyakumar G et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004; 6: 43-54.
37. Hughes BW, Wells AH, Bebok Z et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 1995; 55: 3339-45.
38. Deharvengt S, Wack S, Uhring M, Aprahamian M, Hajri A. Suicide gene/ prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2′-deoxyriboside. Pancreas 2004; 28: E54-64.
39. Deharvengt S, Wack S, Aprahamian M, Hajri A. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med 2005; 7: 672-80.
40. Cai X, Zhou J, Lin J, Sun X, Xue X, Li C. Experimental studies on PNP suicide gene therapy of hepatoma. J Huazhong Univ Sci Technolog Med Sci 2005; 25: 178-81.
41. Cai XK, Zhou JL, Zhou HJ, Zhang L, Wu JH, Lin JS. [Killing effect of PNP/ MeP-dR suicide gene system driven by an AFP promoter AF0.3 on AFP-positive hepatoma cells.] Ai Zheng 2006; 25: 1334-9. (In Chinese.)
42. Kikuchi E, Menendez S, Ozu C et al. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 2007; 14: 279-86.
43. Love SH, Remy CN. Metabolism of methylated purines in Escherichia coli: derepression of purine biosynthesis. J Bacteriol 1966; 91: 1037-49.
44. Persing DH, Smith TF, Tenover FC, White TJ, eds. Diagnostic Molecular Microbiology: Principles and Applications. Washington DC: American Society for Microbiology, 1993.
45. Roth JR. Genetic techniques in studies of bacterial metabolism. Meth Enzymol 1970; 17: 3-35.
46. Gao T, Li WZ, Liang SH et al. Enzymatic synthesis of 6-methylpurine-2′-deoxyriboside by recombinant purine nucleoside phosphorylase. Industrial Microbiol 2007; 37: 8-13.
47. Mosmann T. Rapid colorimetric assay for celluar growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55.
48. Sasaki DT, Dumas SE, Engleman EG. Discrimination of viable and non-viable cells using propidium iodide in two color immunofluorescence. Cytometry 1987; 8: 413-20.
49. Tanaka T, Kanai F, Okabe S et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 1996; 56: 1341-5.
50. Theys J, Landuyt W, Nuyts S et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 2001; 8: 294-7.
51. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002; 25: 218-25.
52. Schoen C, Stritzker J, Goebel W, Pilgrim S. Bacteria as DNA vaccine carriers for genetic immunization. Int J Med Microbiol 2004; 294: 319-35.
53. Critchley RJ, Jezzard S, Radford KJ et al. Potential therapeutic applications of recombinant, invasive E. coli. Gene Ther 2004; 11: 1224-33.
54. Gallucci S, Lolkema ML, Matzinger P. Natural adjuvants: Endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-55.
55. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
56. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10: 399-415.
57. Melero I, Vile RG, Colombo MP. Feeding dendritic cells with tumor antigens: Self-service buffet or a la carte? Gene Ther 2000; 7: 1167-70.
58. Lee CH, Wu CL, Shiau AL. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 2004; 6: 1382-93.
59. Platt J, Sodi S, Kelley M et al. Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur J Cancer 2000; 36: 2397-402.
60. Mengesh AL, Dubois P, Lambin W et al. Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated salmonella. Cancer Biol Ther 2006; 5: 1120-28.